Optimizing the structure of TTR Ligands for Half-life Extension (TLHE) of Peptides
Introduction/Abstract
The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys.
Location
DUC Ballroom A&B
Format
Poster Presentation
Optimizing the structure of TTR Ligands for Half-life Extension (TLHE) of Peptides
DUC Ballroom A&B
The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys.